TGFB1 and pulmonary fibrosis: The top pathways predicted to be positively affected by TGFβ treatment included idiopathic pulmonary fibrosis signaling and hepatic fibrosis/stellate cell activation, as well as the osteoarthritis pathway and axonal guidance signaling.